Menopause (Support and Services) Bill

Sara Britcliffe Excerpts

2nd reading
Friday 29th October 2021 Commons Chamber

[Jackie Doyle-Price]

I could not possibly disagree with that. The really sad thing is that it has taken a century of women having the vote to get to a critical mass where we can now finally discuss these things. I hope that we will make up for lost time. This Bill is a very important one.

One of the most important things that this Bill will achieve is that society will start taking these subjects seriously. There is so much about women’s health that has been taboo for a very long time. I have spoken a lot previously about problem periods, and about the fact that endometriosis continues to go undiagnosed, causing massive problems for women and girls who suffer with it. It says everything. Again, one in three women suffer fibroids. We all think that it is normal. We all think that this is what a woman’s lot is, and we are encouraged to suffer in silence, and it really should not be that way. It is interesting to make that observation in the wake of the Cumberlege report, “First Do No Harm”, which, obviously, looked at these issues from the perspective of vaginal mesh.

Over and over again, we see the same issues raised. Women are not heard. The quality of conversations that women have with their medical practitioners is just not good enough. Too often, women feel fobbed off. That struck me when I was a Minister in the Department of Health and Social Care. A number of female colleagues would share with me their experiences. I just thought, “For goodness’ sake, we are pushy, opinionated women who are elected to this House! If we are not being heard, then God help the rest of the female population.” It is really important that we shine light on what can be expected. As the hon. Member for Swansea East so eloquently explained, presenting to a GP with symptoms, which ended up with her being sent away with a prescription for anti-depressants for something that all women will go through just is not good enough. I cannot believe that we are still having this conversation. The more that society in general understands what comes with menopause, the more that we will be able to have those sensible conversations and the more that we will be able to manage our conditions well. We must acknowledge this throughout society. We have to start in schools and make sure that everyone understands the life course around women’s health and what they will go through.

[Sara Britcliffe (Hyndburn) (Con)]

I thank my hon. Friend for giving way and the hon. Member for Swansea East (Carolyn Harris) for bringing this Bill forward. On educating people, one of the first times that I actually understood this issue was as a result of this Bill, so it is key for women and men to learn about the subject at a young age so that we can go forward.

[Jackie Doyle-Price]

My hon. Friend puts that extremely well. The fact of the matter is that, even as women who are well-informed and interested in this subject, we still do not necessarily know what to expect. It is also the case that boys and men need to understand these things too.

Hon. Members will know that I chair the all-party pharmacy group and I can advise the House that the National Pharmacy Association is fully in support of this Bill. It fully supports the exemption of HRT from prescription charges. It also expressed its willingness to play a much bigger role in terms of the education and support of women going through menopause. We know that, a lot of the time, the conversations that patients can have with their pharmacists are less intimidating and less formal than those they might have with their GP. Again, lots of things are available over the counter that can help alleviate the symptoms of menopause, but also a lot of advice can be given about generally looking after wellbeing. I say to the Minister that I know that pharmaceutical bodies will be very keen to play their role in making sure that there is a much wider understanding and in giving more support to women going through the menopause.

My hon. Friend the Member for Devizes (Danny Kruger) raised the important issue of the half a billion pounds of potential waste of prescriptions. We must make better use of pharmacists to review prescriptions, because they often tend to know more about the drugs that are being dispensed than thfe GPs who are writing the prescriptions. If we can play a better role in enabling pharmacists to review the prescriptions that their patients are presenting to them, we might go a long way to making those savings and getting more bang for our buck from the billions of pounds that we spend on our NHS. I encourage the Minister to look constructively at that suggestion, because the issue of misdiagnosis and the cost of drugs is significant.

The hon. Member for Swansea East has raised the issue of vaginal dryness. That leads me to make the observation that if we had applied as much attention to vaginal atrophy as we had to erectile dysfunction, we would be much better off—wouldn’t we? I cannot help but come to the conclusion that if this were happening to men, we might be in a better place. Look at what happened when Viagra was invented: within a year, it became available over the counter. That really begs the question of whether women are being treated fairly in this context. It does not feel like it to me. Again, I am sure that the Minister will be quite sympathetic to that point.

I ask the Government to look constructively at that issue, because we could liberate some of these drugs and make them more available over the counter. We have recently made the mini-pill available over the counter, which is really important given that one in three pregnancies is unplanned, and increasingly those unplanned pregnancies are women in their 30s, rather than teenagers. We have got to the right place when it comes to making contraception more available over the counter, but it took an awfully long time—much longer than making Viagra available over the counter. We must take these matters seriously.

On the subject of vaginal atrophy, I pay tribute to my constituent Sue Moxley. Sue used to be the beauty editor of The Sun. She is now better known for being the singing partner of her husband, David Van Day. She has spoken very publicly about her issues with vaginal atrophy. Again, she echoed the point that it happened to her completely unexpectedly. She was not prepared for it at all and it was incredibly difficult for her to find out information about what she was going through. In the end, having had a number of referrals, she experienced a direct laser-based treatment from Italy to improve the supply of collagen to the vagina, and it was transformational. I ask the Minister to look at that treatment. It is a direct physical treatment; it will not suit everybody, but neither does HRT. We have to ensure that we have a diverse range of treatments available, depending on people’s conditions, because, as the hon. Lady mentioned, everyone’s experience of menopause is very different.

One other issue that Sue raised with me was that it was suggested to her that women who have not experienced childbirth tend to suffer menopause worse. That raises another question, because if that is true, women should all know about it. There is lots about our life courses and experiences that will impact our health, but I would suggest that not enough research is being done into these things. For 51% of the population, I think we deserve better, so I encourage the Minister to look at that.

I have a few final points. The hon. Lady mentioned that HRT has had a bad press. A study in—I think—2001 suggested an increased risk of breast cancer as a consequence of HRT. In fact, that increase was very small, and the impact that study has had on women’s wellbeing has been far more damaging. Let us look at what goes on further through life. If more women were encouraged to take HRT, there would be massive savings for the Government. When we look at social care and why people go into residential care towards the end of their lives, we see that one of the biggest causes is falls and frailty. If we could encourage more women to take HRT—if it suits them—we would have fewer problems with osteoporosis and the injuries that lead to it. It makes perfect sense—we are spending to save.